Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant

The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025

FDA approves Bristol Myers Squibb’s Cobenfy

A first-in-class muscarinic agonist for the treatment of schizophrenia in adults

Alembic receives USFDA final approval for Paliperidone ER tablets

Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia

Allergan Aesthetics drives India’s potential in the global aesthetic market

The International Society of Aesthetic Plastic Surgery reported that non-surgical procedures outnumbered surgical ones globally in 2020

AbbVie completes acquisition of Cerevel Therapeutics

Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia

HCG Manavata Cancer Centre completes world-first in robotic-assisted nipple sparing mastectomy

Steps taken by India for preparedness against future pandemics

Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting

Alembic receives USFDA’s final approval for Fluphenazine Hydrochloride Tablets

Rusan Pharma’s API plant in Ankleshwar receives USFDA GMP approval

Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well

Fischer Medical Ventures and The Therapy Platform partner for mental healthcare

Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions